Skip to main content

Advertisement

Log in

Optimizing the antihormonal treatment and prevention of breast cancer

  • Special Review
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

The incidence of breast cancer is rising throughout the world. Breast cancer is slowly becoming more prevalent in countries which previously had low rates of cancer as well as becoming a leading cause of cancer death in some countries. Fortunately, a large number of these tumors are estrogen receptor (ER) positive and respond to anti-hormonal adjuvant therapy which until recently has been 5 years of tamoxifen treatment. Unfortunately, a significant number of patients develop recurrent cancers and the recurrent tumors are resistant to tamoxifen treatment. In addition, because of tamoxifen’s selective estrogenic actions, there have been reports of venous thrombosis, endometrial cancer, and strokes in patients receiving tamoxifen therapy. Thus, there are other novel therapies such as aromatase inhibitors that block estrogen production in postmenopausal women or fulvestrant that destroys the estrogen receptor. This paper will summarize the therapeutic options for anti-hormonal therapy, the role of anti-hormonal agents in advanced breast cancer, and adjuvant therapy and the current status of chemoprevention with selective ER modulators.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McPherson K, Steel CM, Dixon JM: (ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics).BMJ 321 (7261):624–628, 2000.

    Article  CAS  Google Scholar 

  2. Breast Cancer Facts and Figures.American Cancer Society. 2005–2006.

  3. Kols A: (Breast Cancer; increasing incidence, limited options).Outlook 19:1–8, 2002.

    Google Scholar 

  4. Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T: (Cancer incidence and incidence rates in Japan in 2000: estimates based on data from 11 population-based cancer registries).Jpn J Clin Oncol 36:668–675, 2006.

    Article  Google Scholar 

  5. Japanese Cancer Society:http://www.jcancer.jp/en/screening.html. 2005.

  6. Vital Statistics of Japan: Statistics and Information Department. Minister’s Secretariat, Ministry of Health, Labour and Welfare. 2001.

  7. Japanese Cancer Society: http://www.ncc.go.jp/en/statistics/2005/index.html. 2005.

  8. Mettlin C: Global breast cancer mortality statistics. CA.Cancer J Clin 49:138–144, 1999.

    Article  CAS  Google Scholar 

  9. Tung HT, Tsukuma H, Tanaka H, Kinoshita N, Koyama Y, Ajiki W, Oshima A, Koyama H: (Risk factors for breast cancer in Japan, with special attention to anthropometric measurements and reproductive history).Japanese Journal of Clinical Oncology 29:137–146, 1999.

    Article  CAS  Google Scholar 

  10. Li CI, Daling JR, Malone KE: (Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998).J Clin Oncol 21:3–4, 2003.

    Article  Google Scholar 

  11. Anderson WF, Chatterjee N, Ershler WB, Brawley OW: (Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database).Breast Cancer Research and Treatment 76:27–36, 2002.

    Article  CAS  Google Scholar 

  12. Nomura Y, Tashiro H, Hamada Y, Shigematsu T: (Relationship between estrogen receptors and risk factors of breast cancer in Japanese pre-and postmenopausal patients).Breast Cancer Res Treat 4:37–43, 1984.

    Article  CAS  Google Scholar 

  13. Matsumoto K, Sakamoto G, Nomura Y: (International comparisons concerning breast cancer and steroid receptors).Anticancer Research 6:621–624, 1986.

    CAS  PubMed  Google Scholar 

  14. McGuire WL, Carbone PP, Sears ME, Escher GC: Estrogen receptors in human breast cancer: an overview. In: Estrogen Receptor in Human Breast Cancer. McGuire WL, Carbone PP, Volmer EP eds Raven Press, New York, pp 1–7, 1975.

    Google Scholar 

  15. Nomura Y, Kobayashi S, Takatani O, Sugano H, Matsumoto K, McGuire WL: (Estrogen receptor and endocrine responsiveness in Japanese versus American breast cancer patients).Cancer Res 37:106–110, 1977.

    CAS  PubMed  Google Scholar 

  16. Jensen EV, Jacobson HI: (Basic guides to the mechanism of estrogen action).Recent Progr Hormone Res 18:387–414, 1962.

    CAS  Google Scholar 

  17. Jensen EV, Jordan VC: (The estrogen receptor: a model for molecular medicine. The Dorothy P. Landon AACR Prize for Translational Research).Clin Cancer Res 9:1980–1989, 2003.

    CAS  PubMed  Google Scholar 

  18. Russo J, Fernandez SV, Russo PA, Fernbaugh R, Sheriff FS, Lareef HM, Garber J, Russo IH: (17-Beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells).Faseb J 20:1622–1634, 2006.

    Article  CAS  Google Scholar 

  19. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R, Sutter T: (Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention).Biochim Biophys Acta 1766:63–78, 2006.

    CAS  PubMed  Google Scholar 

  20. NCI Website: http://cancer.gov.cancertopics/understandingcancer.

  21. EBCTCG: (Tamoxifen for early breast cancer: an overview of the randomised trials).Lancet 354:1451–1467, 1998.

    Google Scholar 

  22. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: (Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study).J Natl Cancer Inst 90:1371–1388, 1998.

    Article  CAS  Google Scholar 

  23. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A: (A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group).Cancer 79:730–739, 1997.

    Article  CAS  Google Scholar 

  24. de Ziegler D, Mattenberger C, Luyet C, Romoscanu I, Irion NF, Bianchi-Demicheli F: (Clinical use of aromatase inhibitors (AI) in premenopausal women).J Steroid Biochem Mol Biol 95(1-5):121–127, 2005.

    Article  Google Scholar 

  25. Johnston S: (Fulvestrant and the sequential endocrine cascade for advanced breast cancer).British J Cancer 90 Suppl 1:s15–18, 2004.

    Article  Google Scholar 

  26. Jonat W: (Goserelin (Zoladex)-its role in early breast cancer in pre-and perimenopausal women).Br J Cancer 85 Suppl 2:1–5, 2001.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Jordan VC: (Tamoxifen: a most unlikely pioneering medicine).Nature Reviews Drug Discovery 2:205–213, 2003.

    Article  CAS  Google Scholar 

  28. Furr BJ, Jordan VC: (The pharmacology and clinical uses of tamoxifen).Pharmacol Ther 25:127–205, 1984.

    Article  CAS  Google Scholar 

  29. Cole MP, Jones CT, Todd ID: (A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474).Br J Cancer 25:270–275, 1971.

    Article  CAS  Google Scholar 

  30. Jordan VC, Allen KE: (Evaluation of the antitumour activity of the non-steroidal antioestrogen monohy-droxytamoxifen in the DMBA-induced rat mammary carcinoma model).Eur J Cancer 16:239–251, 1980.

    Article  CAS  Google Scholar 

  31. Jordan VC: Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy. Reviews on Endocrine-Related Cancer (October Supplement):49–55, 1978.

  32. EBCTCG: (Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials).Lancet 365:1687–1717, 2005.

    Article  Google Scholar 

  33. Osborne CK: (Tamoxifen in the treatment of breast cancer).N Engl J Med 339:1609–1618, 1998.

    Article  CAS  Google Scholar 

  34. Howell A, Dodwell DJ, Anderson H, Redford J: (Response after withdrawal of tamoxifen and progestogens in advanced breast cancer).Ann Oncol 3:611–617, 1992.

    Article  CAS  Google Scholar 

  35. Gottardis MM, Jordan VC: (Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration).Cancer Res 48:5183–8187, 1988.

    CAS  PubMed  Google Scholar 

  36. Jordan VC: (Selective estrogen receptor modulation: concept and consequences in cancer).Cancer Cell 5:207–213, 2004.

    Article  CAS  Google Scholar 

  37. Miller WR, Dixon JM: (Antiaromatase agents: preclinical data and neoadjuvant therapy).Clin Breast Cancer Suppl 1:S9–14, 2000.

    Article  Google Scholar 

  38. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D: (Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group).Cancer 83:1142–1152, 1998.

    Article  CAS  Google Scholar 

  39. Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergot I, Erikstein B, Webster A, Morris C: (Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment).J Clin Oncol 20:3396–3403, 2002.

    Article  CAS  Google Scholar 

  40. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A: (Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial).J Clin Oncol 20:3386–3395, 2002.

    Article  CAS  Google Scholar 

  41. Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P: (Switching to anastrozole versus continued tamoxifen treatment for early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial).J Clin Oncol 23:5138–5147, 2005.

    Article  CAS  Google Scholar 

  42. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM: (A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer).N Engl J Med 350:1081–1092, 2004.

    Article  CAS  Google Scholar 

  43. Goss PE, Ingle JN, Marino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL: (A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for earlystage breast cancer).N Engl J Med 349:1–10, 2003.

    Article  Google Scholar 

  44. ATAC Trialists’ Group: (Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial).Lancet 359:2134–3139, 2002.

    Google Scholar 

  45. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, Group AT: (Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer).Lancet 365:60–62, 2005.

    Article  CAS  Google Scholar 

  46. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardly A, Price KN, Goldhirsch A, BIG (Breast International Group), Group I-C: (A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer).N Engl J Med 353:2747–2757, 2005.

    Article  Google Scholar 

  47. Jordan VC: (Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinoma).Eur J Cancer 12:419–424, 1976.

    Article  CAS  Google Scholar 

  48. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N: (Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study).J Natl Cancer Inst 97:1652–1662, 2005.

    Article  CAS  Google Scholar 

  49. Jordan VC: (Optimising endocrine approaches for the chemoprevention of breast cancer. Beyond the Study of Tamoxifen and Raloxifene (STAR) Trial).European Journal of Cancer 42:2909–2913, 2006.

    Article  CAS  Google Scholar 

  50. Jordan VC, Phelps E, Lindgren JU: (Effects of anti-estrogens on bone in castrated and intact female rats).Breast Cancer Res Treat 10:31–35, 1987.

    Article  CAS  Google Scholar 

  51. Gottardis MM, Jordan VC: (Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model).Cancer Res 47:4020–4024, 1987.

    CAS  PubMed  Google Scholar 

  52. Jordan VC: (Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations).Cancer Invest 6:589–595, 1988.

    Article  CAS  Google Scholar 

  53. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC: (The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation).JAMA 281:2189–2197, 1999.

    Article  CAS  Google Scholar 

  54. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR: (For the CORE Investigators Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene).J Natl Cancer Inst 96:1751–1761, 2004.

    Article  CAS  Google Scholar 

  55. Jordan VC: Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nature Reviews Cancer (in press) 2007.

  56. Jordan VC: SERMs: meeting the promise of multifunctional medicines. (Commentary). J ournal of the National Cancer Institute (in press) 2007.

    Article  CAS  Google Scholar 

  57. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehren-bacher L, Pajon (jr) ER, Wade I.J.L., Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N: (The Study of Tamoxifen and Raloxifene (STAR): Report of the National Surgical Adjuvant Breast and Bowel Project P-2 Trial).JAMA 295:2727–2741, 2006.

    Article  CAS  Google Scholar 

  58. http://www.ibcsg.org/public/general-pages/trialsJopen/IBIS-II/trial-IBISII.html.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to V. Craig Jordan.

About this article

Cite this article

Patel, R.R., Sharma, C.G.N. & Jordan, V.C. Optimizing the antihormonal treatment and prevention of breast cancer. Breast Cancer 14, 113–122 (2007). https://doi.org/10.2325/jbcs.966

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2325/jbcs.966

Key words

Navigation